Drugs / [68Ga]Ga-Sa-DABI-4
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06419361 | May 2024 → Dec 2025 overdue | cancer, suppressor of tumorigenicity 3 | First Affiliated Hospital of Chongqing Medical University | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [68Ga]Ga-Sa-DABI-4 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06419361 ↗ |
| Action | Activate | “a novel 68Ga-labeled agonist” NCT06419361 ↗ |
| Modality | Diagnostic / imaging agent | “noninvasive positron emission tomography (PET) imaging” NCT06419361 ↗ |
| Route | Intravenous | “single intravenous injection” NCT06419361 ↗ |